137 Aufrufe 137 0 Kommentare 0 Kommentare

    FINAL CVS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds CVS Health Corporation Investors to Join the Class Action Lawsuit

    New York, New York--(Newsfile Corp. - September 9, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS) and certain of its officers.

    Class Definition

    Anzeige 
    Handeln Sie Ihre Einschätzung zu CVS Health!
    Long
    60,66€
    Basispreis
    0,48
    Ask
    × 12,44
    Hebel
    Zum Produkt
    Short
    71,76€
    Basispreis
    0,63
    Ask
    × 9,48
    Hebel
    Zum Produkt
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired CVS securities between February 9, 2022, and April 30, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/CVS.

    Case Details

    The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the forecasts CVS used to determine plan premiums were ineffective at accounting for medical cost trends and health care utilization patterns; (ii) as a result, CVS was likely to incur significant expenses to cover cost increases that were not accounted for in the Company's forecasts and thus not covered by plan premiums; (iii) accordingly, CVS had overstated the profitability of its Health Care Benefits segment; (iv) contrary to Defendants' assurances, the revenues generated from the Company's other primary segments were insufficient to offset the negative financial impact of the increasing expenditures within the Health Care Benefits segment; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

    On August 2, 2023, CVS issued a press release announcing the Company's results for the quarter ended June 30, 2023, which revealed that the Company was revising its diluted earnings-per-share ("EPS") guidance range to $6.53 to $6.75 from $6.90 to $7.12. In a Quarterly Report filed on Form 10-Q the United States Securities and Exchange Commission ("SEC") that same day, CVS stated that operating income, which has a direct impact on EPS, "decreased $1.4 billion, or 30.7%, in the three months ended June 30, 2023 compared to the prior year primarily due to declines in the Health Care Benefits segment[.]"

    On this news, CVS's stock price fell $2.04 per share, or 2.73%, to close at $72.32 per share on August 3, 2023.

    What's Next?

    A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/CVS or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in CVS you have until September 10, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

    There is No Cost to You

    We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

    Why Bronstein, Gewirtz & Grossman

    Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contact

    Bronstein, Gewirtz & Grossman, LLC
    Peretz Bronstein or Nathan Miller
    332-239-2660 | info@bgandg.com

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/216590


    The CVS Health Stock at the time of publication of the news with a fall of -1,61 % to 51,25USD on Tradegate stock exchange (09. September 2024, 19:52 Uhr).

    Diskutieren Sie über die enthaltenen Werte

    Die besten Community Beiträge zu CVS Health - 859034 - US1266501006

    Hier stellen wir 3 Kommentare aus der Community passend zu CVS Health vor, die von unseren Nutzenden als besonders interessant, informativ oder als gute Chartanalyse bewertet wurden.


    newsfile
    0 Follower
    Autor folgen

    Verfasst von newsfile
    FINAL CVS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds CVS Health Corporation Investors to Join the Class Action Lawsuit New York, New York--(Newsfile Corp. - September 9, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against CVS Health Corporation ("CVS" or "the Company") …